Management of Pulmonary Embolism with Dabigatran
Initial Treatment and Restarting Dabigatran
- For non-high-risk PE, the European Society of Cardiology recommends initiating anticoagulation without delay while diagnostic workup is in progress, and when oral anticoagulation is initiated, a NOAC (including dabigatran) is recommended in preference to a vitamin K antagonist (VKA) 1, 2
- The initial treatment phase for PE requires parenteral anticoagulation (typically LMWH or fondaparinux) for at least 5 days 3, 1
- If dabigatran was previously initiated properly and then temporarily discontinued, there is no guideline recommendation requiring repeat parenteral anticoagulation before restarting 1, 2
- When restarting anticoagulation after temporary discontinuation, the ESC guidelines do not specify a need for LMWH bridging when resuming a NOAC like dabigatran 1, 2
Specific Clinical Scenarios
- For patients with high-risk PE, initial treatment with unfractionated heparin is recommended, followed by appropriate oral anticoagulation after stabilization 1, 4
- In patients with cancer-associated PE, LMWH is preferred over oral anticoagulants for at least the first 3-6 months of treatment 3, 5
Duration of Anticoagulation
- All patients with PE should receive anticoagulation for at least 3 months 1, 2, 5
- For patients with first PE secondary to a major transient/reversible risk factor, discontinue anticoagulation after 3 months 2, 5
- For unprovoked PE or recurrent VTE not related to major transient risk factors, extended or indefinite anticoagulation is generally recommended 2, 5